Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II intraperitoneal TALL-104 cell therapy in ovarian carcinoma with minimal residual disease
2013-001005-82Phase 2Terminated
- Sponsor
- Galileo Research
- Start
- Feb 2014
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TALL-104 in ovarian cancer, sponsored by Galileo Research. Primary endpoint: Conversion rate to pathological complete response. Started Feb 2014; status: terminated.
02
Drugs
TALL-104
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2013-001005-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001005-82.